嘌呤能受体
嘌呤能信号
肿瘤微环境
癌细胞
癌症
生物
癌症研究
免疫学
免疫系统
细胞生物学
细胞外
受体
腺苷受体
生物化学
遗传学
兴奋剂
作者
Wenhui Jia,Zhao Huang,Zhou Li,Yih‐Cherng Liou,Francesco Di Virgilio,Henning Ulrich,Peter Illéš,Wei Zhang,Canhua Huang,Yong Tang
标识
DOI:10.1016/j.drup.2023.100988
摘要
Purinergic signalling, consisting of extracellular purines and purinergic receptors, modulates cell proliferation, invasion and immunological reaction during cancer progression. Here, we focus on current evidence that suggests the crucial role of purinergic signalling in mediating cancer therapeutic resistance, the major obstacle in cancer treatment. Mechanistically, purinergic signalling can modulate the tumor microenvironment (TME), epithelial-mesenchymal transition (EMT) and anti-tumor immunity, thus affecting drug sensitivity of tumor cells. Currently, some agents attempting to target purinergic signalling either in tumor cells or in tumor-associated immune cells are under preclinical or clinical investigation. Moreover, nano-based delivery technologies significantly improve the efficacy of agents targeting purinergic signalling. In this review article, we summarize the mechanisms of purinergic signalling in promoting cancer therapeutic resistance and discuss the potentials and challenges of targeting purinergic signalling in future cancer treatment.
科研通智能强力驱动
Strongly Powered by AbleSci AI